MyFinsight
Home
Blog
About
Maturities and sales of
marketable securities
$13,000K
(-59.33%↓ Y/Y)
Proceed from the
exercise of common stock...
$135K
(-47.47%↓ Y/Y)
Net cash provided by
(used in) investing...
$8,243K
(-47.09%↓ Y/Y)
Net cash provided by
financing activities
$132K
(-47.62%↓ Y/Y)
Canceled cashflow
$4,757K
Canceled cashflow
$3K
Net increase
(decrease) in cash and cash...
$261K
(-75.92%↓ Y/Y)
Canceled cashflow
$8,114K
Purchase of marketable
securities
$4,754K
(-70.96%↓ Y/Y)
Purchase of property and
equipment
$3K
(-83.33%↓ Y/Y)
Accrued liabilities
$1,302K
(179.25%↑ Y/Y)
Share-based compensation
$1,118K
(-31.75%↓ Y/Y)
Prepaid expenses and
other assets
-$164K
(-136.20%↓ Y/Y)
Amounts receivable
-$57K
(24.00%↑ Y/Y)
Non-cash lease expense
$22K
(-45.00%↓ Y/Y)
Depreciation
$12K
(-14.29%↓ Y/Y)
Principal payments on
finance lease...
$3K
(-40.00%↓ Y/Y)
Net cash used in
operating activities
-$8,114K
(44.98%↑ Y/Y)
Canceled cashflow
$2,675K
something is missing
$10,035K
Interest income
$855K
(12.95%↑ Y/Y)
Net loss
-$10,139K
(34.19%↑ Y/Y)
Canceled cashflow
$10,890K
Accounts payable
-$481K
(-249.84%↓ Y/Y)
Amortization of discounts on
marketable securities
$169K
(-61.68%↓ Y/Y)
Operating loss
-$20,980K
(-29.90%↓ Y/Y)
Other income, net
-$42K
Income tax expense
$7K
(-41.67%↓ Y/Y)
Total operating
expenses, excluding...
$19,040K
(31.19%↑ Y/Y)
Total share-based
compensation
$1,940K
(18.44%↑ Y/Y)
Back
Back
Cash Flow
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)
source: myfinsight.com